US EditionSuccessful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
- Ajinomoto Co., Inc. And RIBOMIC Inc. Disclosed joint research on December 27, 2023, showing extended half-life of nucleic acid aptamer conjugates in blood.
- The research advances the development of next-generation aptamer-based drugs by attaching nucleic acid aptamers to the Fc portion of antibodies to prolong their presence in the bloodstream.
- The researchers investigated how the number of aptamers attached and the design of the connecting segment between the antibody’s Fc portion and nucleic acid aptamers affect performance, finding that setting the attachment ratio to one-to-one notably enhances the aptamers' stability in the bloodstream.
- In fiscal 2023, Ajinomoto Group recorded sales of 1.4392 trillion yen, equivalent to 9.9 billion U.S. Dollars, and emphasizes their slogan "Eat Well, Live Well."
- The joint research demonstrates AJICAP technology's potential application to antibody-drug conjugates and various modalities, addressing challenges of antibody drug efficacy and stability.
Insights by Ground AI
Does this summary seem wrong?
64 Articles
64 Articles
All
Left
7
Center
19
Right
3
Coverage Details
Total News Sources64
Leaning Left7Leaning Right3Center19Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
L 24%
C 66%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
